ArticleCell reports. Medicine2024
A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers.
Open access · goldAbstract read
In one paragraph
Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial.British journal of cancer · 2024Trial
- Co-treatment of Colchicine and Rosiglitazone synergistically inhibits cytokine-driven inflammation and modulates the related hsa-miRNA26a-5p, hsa-miRNA21-5p, and STAT3 expression in non-small cell lung cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Malignant craniopharyngiomas: Institutional experience and literature review.Brain pathology (Zurich, Switzerland) · 2026Review
- TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.International journal of cancer · 2026Article
- Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies.Cellular & molecular biology letters · 2026Review
- Periosteal Osteosarcoma: Emerging Clinical Concepts, Evolving Treatment Options: A Narrative Review.Current pain and headache reports · 2025Review
- BOGO: A Proteome-Wide Gene Overexpression Platform for Discovering Rational Cancer Combination Therapies.bioRxiv : the preprint server for biology · 2025Article
- PD-L1 levels, TP53 mutation profiles, and survival outcomes in pancreatic cancer differ by immune-nutritional status.World journal of surgical oncology · 2025Article
- Review
- Dual dimeric interactions in the nucleic acid-binding protein Sac10b lead to multiple bridging of double-stranded DNA.Heliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Mohammed M AlruwailiDepartment of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA; Department of Medical Laboratory Technology, College of Applied Medical Science, Northern Border University, Arar City, Saudi Arabia.
Justin ZonnevilleDepartment of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Maricris N NaranjoDepartment of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Hannah SerioDepartment of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Thomas MelendyDepartment of Microbiology and Immunology, University at Buffalo, Buffalo, NY 14214, USA.
Robert M StraubingerDepartment of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14214, USA; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Bryan GillardDepartment of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14214, USA.
Barbara A FosterDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Priyanka RajanDepartment of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Kristopher AttwoodDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Sarah ChatleyDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Renuka IyerDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Christos FountzilasDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. Electronic address: christos.fountzilas@roswellpark.org.
Andrei V BakinDepartment of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. Electronic address: andrei.bakin@roswellpark.org.
Roswell Park Comprehensive Cancer Center · USUniversity at Buffalo, State University of New York · USNorthern Border University · SA
Funding
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6MSummer Research Experiences in Quantitative Cancer Sciences and Emerging TechnologiesR25CA181003 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI PAMELA A HERSHBERGER, Mukund Seshadri · 2014 to 2026
$3.3MTumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortiumR01CA198096 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI CLYNES, MARTIN, MA, WEN WEE · 2015 to 2019
$2.2MNovel synthetic lethality strategy for TP53 mutant colorectal cancerR37CA282430 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Christos Fountzilas · 2023 to 2026
$2.1MMECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTSR01CA089259 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MELENDY, THOMAS · 2001 to 2005
$1.4MAcquisition of High Performance Data and Computing Infrastructure to Advance Biomedical ResearchS10OD024973 · OD · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI FURLANI, THOMAS · 2019 to 2019
$1.0MSlowing of the polyomavirus DNA replication fork in response to DDRR21AI164081 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MELENDY, THOMAS · 2021 to 2022
$439kA novel DNA damage response that inhibits polyomavirus DNA replicationR21AI128421 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MELENDY, THOMAS · 2017 to 2018
$436kA Novel Treatment Strategy for Metastatic Breast CancerR21CA259719 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI BAKIN, ANDREI V. · 2022 to 2023
$429kNCI NIH HHS P30 CA016056NCI NIH HHS R01 CA089259NCI NIH HHS R01 CA198096NCI NIH HHS R21 CA259719NCI NIH HHS R25 CA181003NCI NIH HHS R37 CA282430NIAID NIH HHS R21 AI128421NIAID NIH HHS R21 AI164081NIH HHS S10 OD024973
Abstract
The tumor-suppressor p53 is commonly inactivated in colorectal cancer and pancreatic ductal adenocarcinoma, but existing treatment options for p53-mutant (p53
Indexed as
Colorectal NeoplasmsPancreatic NeoplasmsDNADNA RepairHumansPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesThymidineTumor Suppressor Protein p53DNAPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesThymidineTumor Suppressor Protein p535-fluorodeoxyuridinecolorectal cancerDNA damagepancreatic cancerPARP inhibitorpatient-derived xenograftpoly(ADP-ribose) polymeraseTAS102trifluorothymidine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.